Literature DB >> 2219291

Specific suppression of allograft rejection by soluble class I antigen and complexes with monoclonal antibody.

R Sumimoto1, N Kamada.   

Abstract

In this experiment, we investigated the effect of daily injection or continuous slow infusion of either DA (MHC haplotype, RT1a) serum or soluble DA class 1 MHC antigen or its complexes with monoclonal antibody on rejection of heterotopic heart allograft in the combination of PVG.RT1a (RT1a) donor into PVG (RT1c) recipient. DA serum delayed significantly both the early and late rejection of PVG.RT1a heart grafts in PVG recipients. Removal of soluble class I MHC antigen from DA serum by affinity chromatography on a monoclonal anti-class I antibody column completely abolished the immunosuppressive effect. Continuous infusion of purified soluble class I antigen from DA rat liver, even from day 4 after heart grafting, induced a significant prolongation of graft survival. This effectiveness was donor-specific and amplified by the mixture of monoclonal anti-class 1 (RT1a) antibody with DA serum--this being induced only by using continuous infusion but not by daily injection. The results indicate that soluble class I antigen can act as a specific immunosuppressive agent in allograft rejection and that its effect is amplified by monoclonal anti-class 1 antibody.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2219291     DOI: 10.1097/00007890-199010000-00029

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

1.  Expression, by functional proteomics, of spontaneous tolerance in rat orthotopic liver transplantation.

Authors:  Tai-Long Pan; Pei-Wen Wang; Chao-Chen Huang; Shigeru Goto; Chao-Long Chen
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

2.  Examination of serum class I antigen in liver-transplanted rats.

Authors:  R Sumimoto; T Shinomiya
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 3.  Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients.

Authors:  Irena Adamashvili; Roger E Kelley; Thomas Pressly; John C McDonald
Journal:  Rheumatol Int       Date:  2005-06-29       Impact factor: 2.631

4.  The fas and fas ligand pathways in liver allograft tolerance.

Authors:  T L Pan; S Goto; Y C Lin; R Lord; K C Chiang; C Y Lai; Y S Chen; H L Eng; Y F Cheng; T Tatsuma; S Kitano; C L Lin; C L Chen
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 5.  Soluble major histocompatibility complex molecules in immune regulation: highlighting class II antigens.

Authors:  Katerina Bakela; Irene Athanassakis
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

6.  Liver graft induced donor specific unresponsiveness without class I and/or class II antigen differences.

Authors:  S Qian; H Sun; A J Demetris; F Fu; T E Starzl; J J Fung
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

7.  Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL).

Authors:  R Hausmann; N Zavazava; J Steinmann; W Müller-Ruchholtz
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

8.  The role of antibodies in liver graft-induced tolerance in mice: passive transfer of serum and effect of recipient B-cell depletion.

Authors:  U Dahmen; H Sun; Y Li; F Fu; A J Demetris; T E Starzl; S Qian; J J Fung
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

Review 9.  Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular carcinoma: a compromise between the risk of recurrence and the risk of rejection?

Authors:  Roberta Angelico; Alessandro Parente; Tommaso Maria Manzia
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-21

10.  Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats.

Authors:  N Murase; T E Starzl; M Tanabe; S Fujisaki; H Miyazawa; Q Ye; C P Delaney; J J Fung; A J Demetris
Journal:  Transplantation       Date:  1995-07-27       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.